Free Trial
NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Price, News & Analysis

Senti Biosciences logo
$3.21 -0.03 (-0.93%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$3.20 -0.01 (-0.31%)
As of 04/2/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Senti Biosciences Stock (NASDAQ:SNTI)

Key Stats

Today's Range
$3.02
$3.56
50-Day Range
$2.86
$4.72
52-Week Range
$1.52
$16.94
Volume
10,339 shs
Average Volume
781,471 shs
Market Capitalization
$83.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Remove Ads

Senti Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

SNTI MarketRank™: 

Senti Biosciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 281st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Senti Biosciences has received no research coverage in the past 90 days.

  • Read more about Senti Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Senti Biosciences are expected to grow in the coming year, from ($14.54) to ($1.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Senti Biosciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Senti Biosciences is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Senti Biosciences has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Senti Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.35% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently decreased by 43.75%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Senti Biosciences does not currently pay a dividend.

  • Dividend Growth

    Senti Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the float of Senti Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Senti Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Senti Biosciences has recently decreased by 43.75%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Senti Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
  • MarketBeat Follows

    2 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Senti Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,413.00 in company stock.

  • Percentage Held by Insiders

    10.70% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 25.73% of the stock of Senti Biosciences is held by institutions.

  • Read more about Senti Biosciences' insider trading history.
Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Stock News Headlines

Senti Bio files $300M mixed securities shelf
Senti Bio files to sell 52.9M shares of common stock for holders
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Senti Bio reports Q4 EPS (67c), consensus ($3.13)
Senti Bio Appoints Feng Hsiung to Board of Directors
See More Headlines

SNTI Stock Analysis - Frequently Asked Questions

Senti Biosciences' stock was trading at $3.51 at the start of the year. Since then, SNTI stock has decreased by 8.5% and is now trading at $3.21.
View the best growth stocks for 2025 here
.

Senti Biosciences, Inc. (NASDAQ:SNTI) released its quarterly earnings data on Thursday, March, 20th. The company reported ($0.67) earnings per share for the quarter, beating analysts' consensus estimates of ($3.13) by $2.46. The firm had revenue of $5.86 million for the quarter, compared to the consensus estimate of $2.80 million.

Senti Biosciences shares reverse split on the morning of Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI).

Company Calendar

Last Earnings
3/20/2025
Today
4/02/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNTI
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+211.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,060,000.00
Pretax Margin
-23,259.76%

Debt

Sales & Book Value

Annual Sales
$2.56 million
Price / Cash Flow
N/A
Book Value
$15.02 per share
Price / Book
0.21

Miscellaneous

Free Float
4,301,000
Market Cap
$83.47 million
Optionable
Not Optionable
Beta
2.52
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:SNTI) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners